تحلیل داده های دارویی زنان مبتلا به فیبروم رحمی
Abstract
Introduction
Research contents
Research results
Conclusion
References
Abstract
The purpose of this study was to analyze the characteristics of the diagnosis and treatment of female uterine fibroids based on data mining technology and the medication rule. Clinical literature related to the treatment of uterine fibroids by Chinese National Knowledge Infrastructure (CNKI) from 2004 to 2018 were searched, and the literature meeting the requirements were selected according to the inclusion criteria and exclusion criteria. The contents of the prescription were recorded into the database, and the results of drug frequency, common drugs and core rules, etc. were obtained by the rule analysis of the software, so as to analyze the medication rules of modern doctors in treating uterine fibroids. Through research and analysis, it showed that common clinical drugs include leuprorelin (GnRH-a), danazol (androgen), gestrinone (progestin), mifepristone (progesterone receptor antagonist), and some cases of combination therapy. Based on the analysis of the frequency of drug, treatment effect and adverse drug reactions, it was found that the clinical application of mifepristone in the treatment of uterine fibroids was relatively common, with significant drug effect and mild adverse reactions, which was worthy of clinical promotion and application. Therefore, the results of this study provide a new basis for the clinical and basic research of traditional Chinese medicine in the treatment of uterine fibroids, but it still needs the verification of expert interpretation, experimental research and other methods.
Introduction
Uterine fibroids are one of the most common benign tumors in women and are derived from the monoclonal proliferation of uterine smooth muscle cells. Uterine fibroids are more common in women of childbearing age and are greatly affected by estrogen and progesterone. The incidence of uterine fibroids is related to race, with the highest incidence among African Americans, accounting for 80% [1]. In addition, the high-risk factors of fibroids also include age, early menarche, late childbirth, coffee, alcohol abuse, gene mutation, obesity and other problems [2]. There are a variety of clinical manifestations of uterine fibroids, including menorrhagia, prolonged menstruation, pain, anemia, abortion, infertility, abnormal band, bladder and rectal compression symptoms. Uterine fibroids will not only affect the fertility of patients, but also affect the quality of life and psychological status of patients. In terms of infertility, infertility caused by uterine fibroids alone accounts for less than 3% of all infertile patients [3,4]. Studies have shown that normal tissue around the uterus in patients with uterine fibroids contains significantly less estrogen and progesterone receptors than fibroids. In patients with uterine fibroids, the normal tissue surrounding the uterus contains significantly reduced estrogen and progesterone receptors than in fibroid tissue.In 2014,the state food and drug administration has approved Mifepristone (RU486), gonadotropin-releasing hormone agonist (GnRH-a), gossypol and some traditional Chinese medicines for the treatment of uterine fibroids [5,6]. Recent studies have shown that mifepristone not only directly inhibits follicular development and secretion in the ovary, but also may inhibit the secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH). Therefore, the drugs commonly used in the clinical treatment of uterine fibroids are drugs that can reduce the level of estrogen and progesterone. For example, the use of gonadotropin receptor agonists.